The abstract is read at the publisher; the summary is JClub's.
Posaconazole binds two distinct sites on Parechovirus-A3 capsids—VP0–VP1 in US WI-09 and VP3–VP1 in 9C-CMKC and US WI-09 POSA P14—shifting VP0’s contribution from 86% to 0%.
- Why it matters: There are no specific antivirals for PeV-A3 meningoencephalitis in neonates, and emerging post–COVID-19 variants may not be neutralized by existing immunity.
- What they did: Molecular simulations mapped POS conformational dynamics and identified binding-site changes, while infection assays tested replication inhibition in Vero-P and receptor-overexpressing Vero-MYADM cells.
- The result: In Vero-P cells, 0.3 {micro}M POS inhibited replication of US WI-09 and 9C-CMKC, but in Vero-MYADM it inhibited only US WI-09; VP1 Tyr224 substitutions abolished the Tyr224–VP3 anchor.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.